FiercePharma

New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

VENTURE-AF, the First Global, Prospective, Randomized Trial of Any Novel Oral Anticoagulant in this Setting, Presented as Late-Breaking Clinical Trial Raritan, NJ (May 14, 2015) - Janssen ...
TCTMD

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

PARIS, France—To head off the risk of device-related thrombus after left atrial appendage (LAA) occlusion, a reduced dose of rivaroxaban may be a viable alternative to dual antiplatelet therapy (DAPT) ...
FiercePharma

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome Raritan, NJ (May 23, ...
AOL

Does Medicare cover Xarelto?

Medicare Part D and Medicare Advantage plans with prescription drug coverage may cover Xarelto if it appears on the plan’s formulary. A generic version of Xarelto (rivaroxaban) recently became ...